<DOC>
	<DOCNO>NCT01800968</DOCNO>
	<brief_summary>The primary objective test hypothesis , compare placebo , therapy Subcutaneous ( SQ ) GLP-1 agonist post-Acute Heart Failure Syndrome ( AHFS ) discharge period associate great clinical stability six month assess composite clinical endpoint .</brief_summary>
	<brief_title>Functional Impact GLP-1 Heart Failure Treatment ( FIGHT )</brief_title>
	<detailed_description>Hospitalization AHFS identify individual increase risk death re-hospitalization follow discharge . This increase risk justifies intervention novel therapy vulnerable post-discharge period enhance clinical stability prevent early HF mortality readmission . As heart failure ( HF ) progress , impairment metabolism render heart substrate constrain , limit cardiac metabolism . Glucagon-like peptide-1 ( GLP-1 ) naturally occur incretin peptide enhances cellular glucose uptake stimulate insulin secretion insulin sensitivity target tissue . Preclinical early-phase clinical data support GLP-1 effective therapy advance HF use GLP-1 receptor agonist large number patient diabetes reveal good safety profile reduction adverse cardiac outcome .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . AHFS define presence least 1 symptom ( dyspnea , orthopnea , edema ) AND 1 sign ( rales auscultation , peripheral edema , ascites , pulmonary vascular congestion chest radiography ) 3 . AHFS primary cause hospitalization 4 . Prior clinical diagnosis HF 5 . Left Ventricular Ejection Fraction ( LVEF ) ≤ 40 % precede 3 month ( echo within precede 3 month , LVEF ≤ 30 % precede three year acceptable ) 6 . On evidencebased medication HF ( include betablocker ACEinhibitor/ARB ) previously deem intolerant 7 . Use least 80 mg furosemide total daily dose ( equivalent ) prior admission AHFS ( low dose loop diuretic combine thiazide count `` equivalent '' ) 8 . Willingness provide informed consent 1 . AHFS due acute myocarditis acute Myocardial Infarction 2 . Ongoing hemodynamically significant arrhythmia contribute HF decompensation 3 . Inotrope , intraaortic balloon pump ( IABP ) mechanical circulatory support use time consent . Prior use exclude patient . 4 . Current plan leave ventricular assist device therapy next 180 day 5 . United Network Organ Sharing status 1A 1B 6 . Btype natriuretic peptide ( BNP ) &lt; 250 NTproBNP &lt; 1,000 ( Not require per protocol available low would exclusion ; within 48 hour consent ) 7 . Hemoglobin ( Hgb ) &lt; 8.0 g/dl 8 . Glomerular filtration rate ( GFR ) &lt; 20 ml/min/1.73 m2 within 48 hour consent 9 . Systolic blood pressure &lt; 80 mmHg consent 10 . Resting Heart Rate &gt; 110 consent 11 . Acute coronary syndrome within 4 week define electrocardiographic ( ECG ) change biomarkers myocardial necrosis ( e.g . troponin ) appropriate clinical setting ( chest discomfort anginal equivalent ) 12 . Percutaneous Coronary Intervention , coronary artery bypass graft new biventricular pacing within past 4 week 13 . Primary hypertrophic cardiomyopathy 14 . Infiltrative cardiomyopathy 15 . Constrictive pericarditis tamponade 16 . Complex congenital heart disease 17 . Noncardiac pulmonary edema 18 . More moderate aortic mitral stenosis 19 . Intrinsic ( prolapse , rheumatic ) valve disease severe mitral , aortic tricuspid regurgitation 20 . Sepsis , active infection ( exclude cystitis ) comorbidity drive HF decompensation 21 . Acute chronic severe liver disease evidence follow : encephalopathy , variceal bleeding , International Normalized Ration ( INR ) &gt; 1.7 absence anticoagulation treatment 22 . Terminal illness ( HF ) expect survival less 1 year 23 . Previous adverse reaction study drug 24 . Receipt investigational product previous 30 day . 25 . Enrollment plan enrollment another randomize therapeutic clinical trial next 6 month . 26 . Inability comply plan study procedure 27 . Pregnancy breastfeed mother 28 . Women reproductive age adequate contraception 29 . History acute chronic pancreatitis 30 . History symptomatic gastroparesis 31 . Familial personal history medullary thyroid cancer multiple endocrine neoplasia type2 ( MEN2 ) 32 . Prior weightloss surgery ( i.e. , RouxenY gastric bypass ) gastric surgery associate increase endogenous GLP1 production 33 . Prior ongoing treatment GLP1 receptor agonists 34 . Ongoing treatment dipeptidyl peptideIV inhibitor ( 1 week washout require ) 35 . Ongoing treatment thiazolidinedione 36 . Oxygendependent chronic obstructive pulmonary disease 37 . Diabetic patient history 2 severe hypoglycemia , Diabetic Ketoacidosis ( DKA ) hyperglycemic , hyperosmotic nonketotic coma precede 12 month . 38 . Diagnosis Type 1 Diabetes Mellitus 40 . If diabetic , inadequate glycemic control glucose level &gt; 300 mg/dL within 24 hour randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>